Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…

Biotechnology

US, South San Francisco [HQ]

Overview
Fin. Reports
Financials
Leadership & Strategy
Government, Law & Regulation
Employees
More

Earnings Call · Transcripts · Speakers

Earnings Call Transcripts

Earnings Call · Transcripts · Speakers

This analysis tool shows transcript versions of the official earnings calls hosted by Denali Therapeutics Inc.

Could not find a transcript

Transcripts

Could not find a transcript

Peers Transcripts

Peers Analysis

Sorry! None of DNLI's peers has listed transcripts.

SEC Reader

The document search tool might be interesting as well.
Give it a try, to quickly access SEC Filings-

10-K · 10-Q · DEF 14A · S-4

Upcoming Transcript Tools

Full Text Search - Across All Transcripts
Detail Speaker Profiles
Non-US Transcripts